Related to Pharma Touting Phase II/III Wins in Run-Up to ASCO

• Opinion: A Stem of Hope for Cancer Treatments
  Evidence mounts in favor of therapies targeting cancer stem cells.
  
• Customized Cancer Vaccines Finally (Maybe) Arrive
  Positive late-stage trial results are reinstating the potential of a personalized approach to treatment.
  
• Genentech Goes Beyond Antibodies with Bayhill Therapeutics Diabetes Deal
  Limitations with using mAbs for chronic diseases, and negative results from line-extension trials with Avastin are possible reasons.
  
• Denosumab—Great Expectations for Amgen and Osteoporosis Market
  Serious side effects like skin infections requiring hospitalization could limit market penetration.
  
• Sutent—Would Biomarkers Have Helped?
  Recent failures bear out the necessity for marker development alongside drug R&D but also highlight the complexities.
  
• This Year’s Major Mergers—What Makes Sense and What Doesn’t
  Five big pharma firms spend big bucks to fortify businesses.
  
• GEN Exclusive: 2009 Laskers Honor Advances in Stem Cell Technology and Cancer Therapy
  Work cited will revolutionize cancer therapy and impact a potential $700 million global stem cell market.
  
• Making Sense of Antisense and Its Rebound Potential
  Some believe that the amount of time and money spent on the technology has made it ready for a comeback.
  
• Poniard’s Fortunes Likely Rest on Picoplatin
  Disappointing Phase III results in SCLC but promising Phase II results in colorectal cancer make company’s future uncertain.
  
• 2009 in Review: Headline-Making Stories in the Biotech Industry
  Even though last year was marred by the economic crash, the life science sector showed significant progress.
  
• Reporting from J.P. Morgan Healthcare Conference
  Drug companies developing companion diagnostics is just one of the trends highlighted at the meeting.
  
• Cancer Cell Line Identity Crisis
  Researchers weigh in on the impact of incorrectly labeled cell lines on cancer research and drug development.
  
• Antibody-Drug Conjugates to Fight Cancer
  While mAbs have been extremely successful, these empowered antibodies are touted as the next big blockbusters.